$Orphazyme (ORPH.US)$ received a Complete Response Letter fr...
$Orphazyme (ORPH.US)$ received a Complete Response Letter from the FDA. A CRL indicates the FDA has asked the company to make amendments to its trial process, among other things. Following the CRL, Orphazyme cut its FY21 guidance.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
TonyDongeeeee : What does it mean can't read who can explain
3777888 : How u know?
慧怡 TonyDongeeeee :
Anyway, it's just the right thing to buy
TonyDongeeeee : ok